Last updated on August 2018

Safety Pharmacokinetics and Efficacy of Dupilumab in Patients 6 Months to <6 Years With Severe Atopic Dermatitis (Liberty AD PRESCHOOL)


Brief description of study

This study is a 2-part (parts A and B) phase 2/3 study to evaluate the safety, pharmacokinetics (PK) and efficacy of dupilumab in patients 6 months to less than 6 years of age with severe atopic dermatitis (AD).

Detailed Study Description

  1. Part A (open-label, single-ascending-dose, sequential cohort phase 2 study):
    • Primary objective is to characterize the safety and PK of dupilumab administered as a single dose in pediatric patients, 6 months to less than 6 years of age, with severe AD.
    • Secondary objective is to evaluate the efficacy and immunogenicity of a single dose of dupilumab in patients 6 months to less than 6 years of age with severe AD 2. Part B (randomized, double-blind, parallel-group, placebo-controlled phase 3 study):
    • Primary objective is to demonstrate the efficacy of multiple doses of dupilumab over 16 weeks of treatment when administered concomitantly with TCS in pediatric patients, 6 months to less than 6 years of age, with severe AD.
    • Secondary objective is to assess the safety and immunogenicity of multiple doses of dupilumab over 16 weeks of treatment when administered concomitantly with TCS in patients 6 months to less than 6 years of age with severe AD

Clinical Study Identifier: NCT03346434

Contact Investigators or Research Sites near you

Start Over

Clinical Trials Administrator

Regeneron Investigational Site
Birmingham, AL United States
  Connect »

Clinical Trials Administrator

Regeneron Investigational Site
San Diego, CA United States
  Connect »

Clinical Trials Administrator

Regeneron Investigational Site
Centennial, CO United States
  Connect »

Clinical Trials Administrator

Regeneron Investigational Site
Coral Gables, FL United States
  Connect »

Clinical Trials Administrator

Regeneron Investigational Site
Tampa, FL United States
  Connect »

Clinical Trials Administrator

Regeneron Investigational Site
Columbus, GA United States
  Connect »

Clinical Trials Administrator

Regeneron Investigational Site
Macon, GA United States
  Connect »

Clinical Trials Administrator

Regeneron Investigational Site
Boston, MA United States
  Connect »

Clinical Trials Administrator

Regeneron Investigational Site
Minneapolis, MN United States
  Connect »

Clinical Trials Administrator

Regeneron Investigational Site
Saint Louis, MO United States
  Connect »

Clinical Trials Administrator

Regeneron Investigational Site
Forest Hills, NY United States
  Connect »

Clinical Trials Administrator

Regeneron Investigational Site
San Antonio, TX United States
  Connect »

Clinical Trials Administrator

Regeneron Investigational Site
Norfolk, VA United States
  Connect »

Clinical Trials Administrator

Regeneron Investigational Site
Tacoma, WA United States
  Connect »

Clinical Trials Administrator

Regeneron Investigational site
Los Angeles, CA United States
  Connect »

Clinical Trials Administrator

Regeneron Investigational site
Orange, CA United States
  Connect »

Clinical Trials Administrator

Regeneron Investigational Site
Palo Alto, CA United States
  Connect »

Clinical Trials Administrator

Regeneron Investigational Site
Chicago, IL United States
  Connect »

Clinical Trials Administrator

Regeneron Investigational Site
Lebanon, NH United States
  Connect »

Clinical Trials Administrator

Regeneron Investigational Site
Portland, OR United States
  Connect »

Clinical Trials Administrator

Regeneron Investigational Site
Seattle, WA United States
  Connect »

Clinical Trials Administrator

Regeneron Investigational site
Muenster, Germany
  Connect »

Clinical Trials Administrator

Regeneron Investigational Site
Dresden, Germany
  Connect »

Clinical Trials Administrator

Regeneron Investigational site
Frankfurt/ Main, Germany
  Connect »

Clinical Trials Administrator

Regeneron Investigational site
Hamburg, Germany
  Connect »

Clinical Trials Administrator

Regeneron Investigational site
Muenchen, Germany
  Connect »

Clinical Trials Administrator

Regeneron Investigational Site
Manchester, United Kingdom
  Connect »

Clinical Trials Administrator

Regeneron Investigational Site
Sheffield, United Kingdom
  Connect »